The chart below identifies updates to our medical benefit drug program. For additional details, refer to the Medical Necessity Guidelines associated with the medical drug in question, which you can find on our Point32Health (the parent company of Harvard Pilgrim Health Care and Tufts Health Plan) Medical Benefit Drug Medical Necessity Guidelines page.

Alternatively, some medical drugs are managed through an arrangement with OncoHealth when utilized for oncology purposes for Harvard Pilgrim members. You can find information about this program on the OncoHealth page in the Vendor Programs section of Point32Health’s provider website and you can access the prior authorization policies for these drugs directly on OncoHealth’s webpage for Harvard Pilgrim.

Tufts Health Together utilizes MassHealth’s Unified Formulary for pharmacy medications and select medical benefit drugs; for drug coverage and criteria refer to the MassHealth Drug List.


New prior authorization programs for OncoHealth drugs
MNG/Drug(s)Plan & additional information Eff. date 

MassHealth Unified Drugs

Ryoncil

Tufts Health Together

  • Criteria updated to require an additional trial with one NCCN-recommended agent for members ≥12 and <18 years of age in addition to ruxolitinib
  • Appendix updated to follow the current NCCN guidance for recommended alternative treatment options
10/1/2026

Filkri (J3590)

Medical Benefit Step Therapy 

Harvard Pilgrim Commercial 

New-to-market drug now subject to prior authorization/step therapy requirements.

10/1/2026

Denosumab Samsung Bioepis (Ospomyv/Xbryk) (Q5159)

Medical Benefit Step Therapy 

Harvard Pilgrim Commercial 

New-to-market drug now subject to prior authorization/step therapy requirements.

10/1/2026

Vykoura (J3490)

Medical Benefit Step Therapy 

Harvard Pilgrim Commercial 

New-to-market drug now subject to prior authorization/step therapy requirements.

10/1/2026

Armlupeg (J3490)

Medical Benefit Step Therapy 

Harvard Pilgrim Commercial 

New-to-market drug now subject to prior authorization/step therapy requirements.

10/1/2026
Blenrep 

Harvard Pilgrim Commercial 

Blenrep (belantamab mafodotin-blmf, 0.1 mg) (J9037) will be covered when prior authorization has been obtained. 

10/1/2026 

Updates to existing prior authorization programs
MNG/Drug(s)Plan & additional informationEff. date 

MassHealth Unified Drugs

Epioxa

Tufts Health Together

Prior authorization is now required for coverage of Epioxa (J2789), which will be covered when all the criteria specified by MassHealth are met. 

10/1/2026

MassHealth Drug List

MassHealth Acute Hospital Carve-Out Drug List

Tufts Health Together

MassHealth has made updates to the criteria for the following carve-out drugs: 

  • Abecma
  • Breyanzi
  • Carvykti
  • Casgevy
  • Elevidys
  • Encelto
  • Hemgenix
  • Itvisma
  • Kebilidi
  • Kymriah
  • Lenmeldy
  • Luxturna
  • Lyfgenia
  • Omisirge
  • Skysona
  • Yescarta
  • Zevaskyn
  • Zolgensma
10/1/2026
Carelon code list

Harvard Pilgrim Health Care Commercial, Tufts Health Direct, Tufts Health Plan Together, Tufts Health Plan RITogether, Tufts Health One Care

The following codes are now covered with prior authorization: 

  • 0575U
  • 0576U
  • 0578U
  • 0582U
  • 0583U
  • 0585U
  • 0586U
  • 0592U
  • 0597U
10/1/2026